Cell Expansion Market Worth $26.7 Billion

The global cell expansion market in terms of revenue was estimated to be worth $14.3 billion in 2024 and is poised to reach $26.7 billion by 2029, growing at a CAGR of 13.3% from 2024 to 2029.

Some factors contributing to the growth of the global market includes increasing RD investments in cell based research, growing focus on personalized medicine, and increasing number of strategic alliances for the development of novel therapeutics. However, ethical concern regarding cell biology and high cost of cell based therapeutics are expected to hinder market growth.

???????? ???? ??? ??????: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=194978883

The consumables segment accounted for the largest share of the product segment in the cell expansion market in 2023.

Based on products, the cell expansion market is segmented into consumables and equipment. Consumables segment dominated the market in 2023 and is expected to dominate the market in the forecast period. Consumables are further segmented into media, reagents, sera, vessels, and other consumables. The largest share of the segment is attributed to increasing research activities for the development of novel biopharmaceuticals.

The biopharmaceutical production segment is estimated to register the highest growth rate during the forecast period in the cell expansion market.

Based on application, the cell expansion market is segmented into biopharmaceutical production, tissue engineering regenerative medicine, drug screening development, and other applications. The biopharmaceutical production segment is estimated to register the highest growth rate during the forecast period. The rising demand for biopharmaceuticals such as vaccine, monoclonal antibodies, and therapeutic proteins due to increasing incidence of chronic diseases is anticipated to promote the growth of biopharmaceutical production segment in coming years.

The Asia Pacific region is the fastest-growing region of the cell expansion market in 2023.

Based on the region, the cell expansion market is segmented into major regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The Asia Pacific is anticipated to register fastest growth in the cell expansion owing to the increasing research practices in the field of advanced therapies such as tissue engineering and regenerative medicine, high government investments fundings for RD, and growing biotechnology industries.

Key players in the cell expansion market include Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Sartorius AG (Germany), Corning Incorporated (US), Lonza (Switzerland), Terumo Corporation (Japan), Eppendorf SE (Germany), FUJIFILM Corporation (Japan), Bio-Techne (US), Repligen Corporation (US), Getinge AB (Sweden), Miltenyi Biotec (Germany), PerkinElmer Inc. (US), STEMCELL Technologies (Canada), PromoCell GmBH (Germany), HiMedia Laboratories (India), BD (US), Takara Bio Inc. (Japan), Shanghai Duoning Biotechnology Co., Ltd. (Japan), REPROCELL Inc. (Japan), PBS Biotech, Inc. (US), ACROBiosystems (US), Solida Biotech GmBH (Germany), Beijing CytoNiche Biotechnology Co., Ltd. (China), Neuromics (US), Bionet (Spain), and Cellexus (UK).

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific Inc. is a leading science and technology company engaged in manufacturing high-end analytical instruments, laboratory equipment, software, consumables, reagents, and services for scientific research, analysis, discovery, and diagnostics. It focuses on acquiring new consumers through partnerships, collaborations, and expansions in emerging markets like China, India, and South Korea. The company further aims to strengthen its presence in selected geographies, undertaking various organic and inorganic growth strategies. For instance, in May 2023, the company has opened a new sterile drug facility in Singapore that will better enable customers to deliver new medicines and vaccines in the Asia-Pacific market.

Danaher Corporation (US)

Danaher Corporation is a leading life sciences and diagnostics innovator providing a wide range of products and services for medical, industrial, and commercial applications. With this strong global presence, Danaher Corporation is constantly involved in product innovations, which have increased the company’s overall revenue. The company continues to invest in research and development to provide innovative products. For instance, in 2022, the company’s research and development expenses were USD 1.75 billion.

Meck KGaA (Germany)

Merck is a leading provider of solutions and services for research, biotechnology and pharmaceutical drug development and production. The company has a strong global presence across North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The company is focusing on expansion of manufacturing facilities to strengthen its footprints across the globe. For instance, in June 2023, the company invested USD 75.8 million (€ 70 Million) to expand reagent manufacturing in China. Merck KGaA and the Nantong Economic and Technological Development Area (NETDA) signed the corresponding agreement in support of this expansion. The NETDA facility produces cell culture media for Life Science customers.

Trending Reports